2013 Q2 Form 10-Q Financial Statement
#000119312513358412 Filed on September 05, 2013
Income Statement
Concept | 2013 Q2 | 2012 Q2 |
---|---|---|
Revenue | $6.268M | $6.288M |
YoY Change | -0.32% | |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $1.840M | $1.950M |
YoY Change | -5.64% | |
% of Gross Profit | ||
Research & Development | $12.96M | $10.46M |
YoY Change | 23.85% | |
% of Gross Profit | ||
Depreciation & Amortization | $400.0K | $200.0K |
YoY Change | 100.0% | |
% of Gross Profit | ||
Operating Expenses | $14.79M | $12.41M |
YoY Change | 19.2% | |
Operating Profit | -$8.526M | -$6.123M |
YoY Change | 39.25% | |
Interest Expense | $10.00K | $20.00K |
YoY Change | -50.0% | |
% of Operating Profit | ||
Other Income/Expense, Net | ||
YoY Change | ||
Pretax Income | -$8.521M | -$6.101M |
YoY Change | 39.67% | |
Income Tax | $99.00K | -$588.0K |
% Of Pretax Income | ||
Net Earnings | -$8.620M | -$5.513M |
YoY Change | 56.36% | |
Net Earnings / Revenue | -137.52% | -87.67% |
Basic Earnings Per Share | ||
Diluted Earnings Per Share | -$2.317M | -$1.579M |
COMMON SHARES | ||
Basic Shares Outstanding | ||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2013 Q2 | 2012 Q2 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $99.30M | |
YoY Change | ||
Cash & Equivalents | $77.48M | $96.12M |
Short-Term Investments | $21.80M | |
Other Short-Term Assets | $3.200M | |
YoY Change | ||
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $102.5M | |
YoY Change | ||
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $3.818M | |
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $1.624M | |
YoY Change | ||
Total Long-Term Assets | $8.719M | |
YoY Change | ||
TOTAL ASSETS | ||
Total Short-Term Assets | $102.5M | |
Total Long-Term Assets | $8.719M | |
Total Assets | $111.3M | |
YoY Change | ||
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $3.038M | |
YoY Change | ||
Accrued Expenses | $3.586M | |
YoY Change | ||
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $36.98M | |
YoY Change | ||
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | |
YoY Change | ||
Other Long-Term Liabilities | $45.40M | |
YoY Change | ||
Total Long-Term Liabilities | $45.40M | |
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $36.98M | |
Total Long-Term Liabilities | $45.40M | |
Total Liabilities | $82.40M | |
YoY Change | ||
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$89.89M | |
YoY Change | ||
Common Stock | $2.840M | |
YoY Change | ||
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | -$87.05M | |
YoY Change | ||
Total Liabilities & Shareholders Equity | $111.3M | |
YoY Change |
Cashflow Statement
Concept | 2013 Q2 | 2012 Q2 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$8.620M | -$5.513M |
YoY Change | 56.36% | |
Depreciation, Depletion And Amortization | $400.0K | $200.0K |
YoY Change | 100.0% | |
Cash From Operating Activities | -$15.80M | -$10.50M |
YoY Change | 50.48% | |
INVESTING ACTIVITIES | ||
Capital Expenditures | -$700.0K | -$300.0K |
YoY Change | 133.33% | |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $10.60M | -$5.200M |
YoY Change | -303.85% | |
Cash From Investing Activities | $9.900M | -$5.500M |
YoY Change | -280.0% | |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 100.0K | 100.0K |
YoY Change | 0.0% | |
NET CHANGE | ||
Cash From Operating Activities | -15.80M | -10.50M |
Cash From Investing Activities | 9.900M | -5.500M |
Cash From Financing Activities | 100.0K | 100.0K |
Net Change In Cash | -5.800M | -15.90M |
YoY Change | -63.52% | |
FREE CASH FLOW | ||
Cash From Operating Activities | -$15.80M | -$10.50M |
Capital Expenditures | -$700.0K | -$300.0K |
Free Cash Flow | -$15.10M | -$10.20M |
YoY Change | 48.04% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
770000 | ||
us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
54000 | ||
CY2012Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
96122000 | |
CY2013Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3770266 | shares |
CY2012Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
0 | |
CY2013Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3770266 | shares |
CY2013Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
415000 | |
CY2013Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
78300000 | shares |
CY2013Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2013Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3586000 | |
CY2013Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3038000 | |
CY2013Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1356000 | |
CY2013Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
36979000 | |
CY2013Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-5000 | |
CY2013Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2013Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1127000 | |
CY2013Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-87050000 | |
CY2013Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2836000 | |
CY2013Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-89885000 | |
CY2013Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
25072000 | |
CY2013Q2 | us-gaap |
Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
|
38000 | |
CY2013Q2 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
288000 | |
CY2013Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | |
CY2013Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
104000 | |
CY2013Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
111252000 | |
CY2013Q2 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
5141000 | |
CY2013Q2 | us-gaap |
Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
|
10000 | |
CY2013Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
45103000 | |
CY2013Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2013Q2 | us-gaap |
Assets Current
AssetsCurrent
|
102533000 | |
CY2013Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
21798000 | |
CY2013Q2 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
571000 | |
CY2013Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1624000 | |
CY2013Q2 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
21794000 | |
CY2013Q2 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
2706000 | |
CY2013Q2 | us-gaap |
Assets
Assets
|
111252000 | |
CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
77481000 | |
CY2013Q2 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
21794000 | |
CY2013Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2011000 | |
CY2013Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
0 | |
CY2013Q2 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
1247000 | |
CY2013Q2 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
8000000 | |
CY2013Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3818000 | |
CY2013Q2 | agio |
Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
|
22 | Securities |
CY2013Q2 | agio |
Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
1000 | |
CY2013Q2 | agio |
Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
5000 | |
CY2013Q2 | agio |
Eligible Milestone Payments Receivable For Clinical Development
EligibleMilestonePaymentsReceivableForClinicalDevelopment
|
5000000 | |
CY2013Q2 | agio |
Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
|
688000 | |
CY2013Q2 | agio |
Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
|
0 | Securities |
CY2013Q2 | agio |
Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event
PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent
|
22500000 | |
CY2013Q2 | agio |
One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program
OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram
|
25000000 | |
CY2013Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
31074167 | shares |
CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
117661000 | |
CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3616101 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3616101 | shares |
CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
78300000 | shares |
CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1708000 | |
CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
65000 | |
CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3308000 | |
CY2012Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
109000 | |
CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
35113000 | |
CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2000 | |
CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1124000 | |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-72024000 | |
CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2012000 | |
CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-74037000 | |
CY2012Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
25072000 | |
CY2012Q4 | us-gaap |
Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
|
65000 | |
CY2012Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
343000 | |
CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
CY2012Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
85000 | |
CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
137008000 | |
CY2012Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
4875000 | |
CY2012Q4 | us-gaap |
Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
|
15000 | |
CY2012Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
57639000 | |
CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
130144000 | |
CY2012Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
36680000 | |
CY2012Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
571000 | |
CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
22000 | |
CY2012Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
36679000 | |
CY2012Q4 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
2706000 | |
CY2012Q4 | us-gaap |
Assets
Assets
|
137008000 | |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
91297000 | |
CY2012Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
36679000 | |
CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
922000 | |
CY2012Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
0 | |
CY2012Q4 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
1246000 | |
CY2012Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
13700000 | |
CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3565000 | |
CY2012Q4 | agio |
Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
|
30 | Securities |
CY2012Q4 | agio |
Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
1000 | |
CY2012Q4 | agio |
Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
2000 | |
CY2012Q4 | agio |
Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
|
410000 | |
CY2012Q4 | agio |
Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
|
0 | Securities |
dei |
Entity Registrant Name
EntityRegistrantName
|
AGIOS PHARMACEUTICALS INC | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-06-30 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001439222 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0100 | pure | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.9185 | pure | |
us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-2.75 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-5.27 | ||
us-gaap |
Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
|
19731564 | shares | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y5M27D | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3690669 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27803000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23452549 | shares | |
us-gaap |
Revenues
Revenues
|
12536000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2690000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-15850000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-15559000 | ||
us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
23195000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19443000 | ||
us-gaap |
Deferred Revenue Additions
DeferredRevenueAdditions
|
121200000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
13000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15572000 | ||
us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-15848000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
9000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
976000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-2000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1845000 | ||
us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
72000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3688000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
72000 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-12536000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
753000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3930000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
54000 | ||
us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
3317000 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-12536000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-13816000 | ||
us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
|||
us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
266000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-271000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
13915000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24420000 | ||
us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
|||
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
289000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
38086000 | ||
us-gaap |
Depreciation
Depreciation
|
723000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
753000 | ||
us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
289000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
28108000 | ||
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
3595000 | ||
us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
289000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
289000 | ||
agio |
Estimated Performance Period Of Agreement
EstimatedPerformancePeriodOfAgreement
|
P6Y | ||
agio |
Available For Sale Investment Maturity Term Maximum
AvailableForSaleInvestmentMaturityTermMaximum
|
P1Y | ||
agio |
Collaboration Revenue
CollaborationRevenue
|
12536000 | ||
agio |
Number Of Vendors Selling Similar Competitive Products
NumberOfVendorsSellingSimilarCompetitiveProducts
|
0 | Vendor | |
agio |
Proportionate Revenue Recognized
ProportionateRevenueRecognized
|
124300000 | ||
agio |
Requirement To Appoint Number Of Development Candidate By Joint Research Committee
RequirementToAppointNumberOfDevelopmentCandidateByJointResearchCommittee
|
2 | Candidate | |
agio |
Number Of Licensed Programs Type Under Collaboration Agreements
NumberOfLicensedProgramsTypeUnderCollaborationAgreements
|
3 | Licensed_Program | |
agio |
Period Considered For Agreement Termination Notice
PeriodConsideredForAgreementTerminationNotice
|
P90D | ||
agio |
Rent Expense Deferred During Period
RentExpenseDeferredDuringPeriod
|
36000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0113 | pure | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.9905 | pure | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M13D | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3302508 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26520000 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-4.16 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23219492 | shares | |
us-gaap |
Revenues
Revenues
|
12556000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-72000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10169000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-11340000 | ||
us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
50649000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13739000 | ||
us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
3500000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
48000 | ||
us-gaap |
Revenue From Grants
RevenueFromGrants
|
20000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11388000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-10144000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-167000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
308000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-25000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
189000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-21539000 | ||
us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
|||
us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-8006000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-869000 | ||
us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
3317000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
4927000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20014000 | ||
us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
|||
us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
3317000 | ||
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-4513000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
55884000 | ||
us-gaap |
Depreciation
Depreciation
|
537000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
189000 | ||
us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-4513000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
23944000 | ||
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
3595000 | ||
us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
202000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1196000 | ||
agio |
Collaboration Revenue
CollaborationRevenue
|
12536000 | ||
agio |
Rent Expense Deferred During Period
RentExpenseDeferredDuringPeriod
|
17000 | ||
agio |
Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
|
1200000 | ||
agio |
Reduction In Income Tax Benefit Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxBenefitDueToCarrybackOfDeferredTaxAssets
|
600000 | ||
CY2010Q2 | agio |
Expiration Extension Period Under Collaboration Agreement
ExpirationExtensionPeriodUnderCollaborationAgreement
|
P2Y | |
CY2010Q2 | agio |
Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
|
2014-04 | |
CY2011Q4 | agio |
Initial Agreement Period
InitialAgreementPeriod
|
P3Y | |
CY2011Q4 | agio |
Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
|
2016-04 | |
CY2011Q4 | agio |
Extended Agreement Period
ExtendedAgreementPeriod
|
P4Y | |
CY2011Q4 | agio |
Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
|
20000000 | |
CY2011 | agio |
Reversal Of Valuation Allowance On Deferred Tax Assets
ReversalOfValuationAllowanceOnDeferredTaxAssets
|
10700000 | |
CY2012 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
CY2012 | agio |
Available For Sale Investment Maturity Term Maximum
AvailableForSaleInvestmentMaturityTermMaximum
|
P1Y | |
CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0118 | pure |
CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.0480 | pure |
CY2012Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y5M1D | |
CY2012Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3358172 | shares |
CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.18 | |
CY2012Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23219492 | shares |
CY2012Q2 | us-gaap |
Revenues
Revenues
|
6288000 | |
CY2012Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5520000 | |
CY2012Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6101000 | |
CY2012Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7311000 | |
CY2012Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
22000 | |
CY2012Q2 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
20000 | |
CY2012Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6123000 | |
CY2012Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5513000 | |
CY2012Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-7000 | |
CY2012Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1948000 | |
CY2012Q2 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
1785000 | |
CY2012Q2 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
||
CY2012Q2 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
1785000 | |
CY2012Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10463000 | |
CY2012Q2 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
||
CY2012Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-2373000 | |
CY2012Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
91000 | |
CY2012Q2 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-2373000 | |
CY2012Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
12411000 | |
CY2012Q2 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
1798000 | |
CY2012Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
164000 | |
CY2012Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-588000 | |
CY2012Q2 | agio |
Collaboration Revenue
CollaborationRevenue
|
6268000 | |
CY2012Q2 | agio |
Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
|
1200000 | |
CY2012Q2 | agio |
Reduction In Income Tax Benefit Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxBenefitDueToCarrybackOfDeferredTaxAssets
|
600000 | |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0100 | pure |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.9185 | pure |
CY2013Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y5M27D | |
CY2013Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3722963 | shares |
CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2013Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.80 | |
CY2013Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
23452549 | shares |
CY2013Q2 | us-gaap |
Revenues
Revenues
|
6268000 | |
CY2013Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8623000 | |
CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-8521000 | |
CY2013Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10418000 | |
CY2013Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
5000 | |
CY2013Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8526000 | |
CY2013Q2 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8620000 | |
CY2013Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-3000 | |
CY2013Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1836000 | |
CY2013Q2 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
||
CY2013Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12958000 | |
CY2013Q2 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
||
CY2013Q2 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
99000 | |
CY2013Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
329000 | |
CY2013Q2 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
99000 | |
CY2013Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
14794000 | |
CY2013Q2 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
1798000 | |
CY2013Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
99000 | |
CY2013Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
99000 | |
CY2013Q2 | agio |
Collaboration Revenue
CollaborationRevenue
|
6268000 |